How does Liraglutide (Saxenda / Victoza) work?
Daily-injection GLP-1 agonist with fatty-acid modification that allows albumin binding for ~13-hour half-life. Same receptor as Semaglutide; shorter duration means daily injection. In plain terms, Liraglutide (Saxenda / Victoza) is daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Patients on insurance plans that cover Saxenda but not Wegovy
- Users who don't tolerate weekly Semaglutide titration
- Educational reference for the GLP-1 class lineage
References
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity) — Pi-Sunyer X et al., NEJM, 2015
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) — Marso SP et al., New England Journal of Medicine, 2016
- Victoza (liraglutide) — Drugs@FDA approval record (ApplNo 022341) — FDA, Drugs@FDA
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Liraglutide (Saxenda / Victoza)
Last updated 2026-06-06.